The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Beyfortus, the new monoclonal antibody injection, similarly reduces the risk of RSV in infants for about five months—or one ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

A new government program will give pregnant mothers and newborns free access to RSV vaccines, a move that is expected to ...

RSV vaccination for infants and mothers should be administered either in the hospital or directly from a primary health-care ...

Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest ...

BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. iii ...

Starting Nov. 4, all babies born in 2024 able to get the Beyfortus immunization for free through their public health unit, ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up ...